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Available online 18 December 2015A rapidly increasing number of papers describing novel iPSC models for cardiac diseases are being published. To
be able to understand the disease mechanisms in more detail, we should also take the full advantage of the
various methods for analyzing these cell models. The traditionally and commonly used electrophysiological
analysis methods have been recently accompanied by novel approaches for analyzing the mechanical beating-
behavior of the cardiomyocytes. In this review, we provide ﬁrst a concise overview on the methodology for
cardiomyocyte functional analysis and then concentrate on the video microscopy, which provides a promise
for a new faster yet reliablemethod for cardiomyocyte functional analysis.We also showhowanalysis conditions
may affect the results. Development of themethodologynot only serves the basic research on the diseasemodels,
but could also provide themuch needed efﬁcient early phase screeningmethod for cardiac safety toxicology. This
article is part of a Special Issue entitled: Cardiomyocyte Biology: Integration of Developmental and Environmen-
tal Cues in the Heart edited by Marcus Schaub and Hughes Abriel.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Until the latest decade, one of the main challenges in cardiac
research has been the difﬁculty in obtaining cardiac cells for laboratory
and cell culture experiments. Cardiac biopsy is a demanding and high-
risk procedure, which is performed only when advantageous clinically
for the patient. Furthermore, cardiomyocytes from the biopsy can be
cultured in a laboratory only for a very short time period, due to rapid
dedifferentiation. Invention of the protocol for differentiating functional
cardiomyocytes from human pluripotent stem cells in 2003 gave one
solution for the problem [1]. For the ﬁrst years, the starting material
for cardiac differentiation was of embryonic origin, and thus its use in
research was under extensive debate. When Prof. S. Yamanaka and his
research team published an article in 2007 describing how human
ﬁbroblasts can be reprogrammed to pluripotent state by using four
transcription factors (OCT3/4, SOX2, KLF4, and c-MYC), the ethical
concerns of the use of stemcellswere overcome [2,3]. Today, generation
of pluripotent stem cell derived cardiomyocytes is a routine procedure,
and readily differentiated high-quality induced pluripotent stem cellyocyte Biology: Integration of
edited by Marcus Schaub and
rsity of Tampere, Finland.
. This is an open access article underderived cardiomyocytes (iPSC-CMs) are commercially available from
multiple sources (Fig. 1).
Generation of iPSC-CMs has offered a great tool for the research and
resulted in exponential growth of this research ﬁeld. Methods for
reprogramming cells to the pluripotent state, and differentiating them
to functional cardiomyocytes have evolved quickly [4]. Thus, the
number of iPSC based disease models for genetic cardiac diseases has
increased rapidly, providing a huge amount of material to be studied.
Furthermore, high-quality iPSC-CMs have become commercially avail-
able from multiple providers, enabling their use in cardiac research
without the need to have iPSC laboratory. Functional in vitro analysis
of cardiomyocytes is essential for both understanding the pathogenic
mechanisms of cardiac disorders and performing preclinical safety
studies for novel drugs. As Peters and colleagues already in 2012 stated,
there is an urgent need for innovative in vitro assays with sufﬁcient
throughput and quality to enable screening of potential cardiovascular
toxicity of novel potential drugs [5]. It is obvious that the methodology
for functional characterization of the disease models has to develop to
meet these needs. The ideal future methods are fast, yet sensitive and
reliable, and enabling high throughput analysis.
Development of a newdrug is a process with a high rate of failure [6,
7]. Costs of the process increase greatly especially when moving from
preclinical to clinical phase, underlining the importance of thorough
validation of the drug candidates in the early phases of the development
pipeline. The preclinical cardiac safety studies of drug candidatesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Generation of pluripotent stem cell derived cardiomyocytes for cardiac research.
Pluripotent stem cells can be derived directly from the inner cell mass of an embryo
(human embryonic stem cells, hESC) or from differentiated cells of an individual, such
as ﬁbroblasts, via reprogramming (human induced pluripotent stem cells, hiPSC). Both
of these can be differentiated to functional cardiomyocytes for different purposes.
1865E. Laurila et al. / Biochimica et Biophysica Acta 1863 (2016) 1864–1872include assays on the human ether-à-go-go related gene (hERG), a
encoding for a potassium channel protein [8,9]. Inhibition of the
function of this ion channel interferes with cardiac repolarization and
causes prolongation of the QT interval, which may induce serious
ventricular arrhythmias, such as Torsade de Pointes (TdP), and lead to
sudden cardiac death [10]. This is a major cause of adverse clinical
events and withdrawal of drugs from the market [11,12]. Traditionally
the safety studies have been based on stable expression of the hERG
gene in a non-cardiac human cell line (such as HEK293). However,
these transfected cells lack all other cardiac ion channels forming in con-
cert the proper electrical properties of cardiomyocytes and transfected
cells are not an optimal platform to study human cardiotoxicity. Thus,
human iPSC based models have been increasingly searched and tested
for cardiac safety studies, as they provide the whole physiological
expression pattern of the cardiac ion channels [13–16].
Several review articles have been published describing the
progress on generating iPSC based disease models on genetic cardiac
disorders [4,14,16–19]. However, much less attention has been paid
on the methods actually used for characterizing functionality of these
models. In this review article, we give an overview of the methodology
for studying the functionality of pluripotent stem cell derived
cardiomyocytes, with a special emphasis on the rapidly evolving ﬁeld
of assessment based on videomicroscopy (See Fig. 2).We also highlight
the importance of optimizing and standardizing the analysis conditions,
and give some examples how they might affect the results.
2. Cardiomyocyte functionality analysis
2.1. Methods for analyzing electrophysiology
2.1.1. Patch clamp
Traditionally, methods analyzing cardiomyocytes have been almost
solely based on the electrophysiology of the cells. Patch clamp provides
detailed data on ion currents, and is often referred to as the gold
standard for cardiomyocyte analysis due to its sensitivity and ability to
detect currents directly from the cell [20]. However, it is invasive as it
breaks the cell membrane and requires a strong seal (giga seal), thus
enabling only a short term measurement. Additionally, it is a terminal
experiment leading to cell death. Patch clamp is also not an efﬁcient
screening method due to the relatively long time needed per one mea-
surement, expensive instrumentation, and the sophisticated skills re-
quired from the personnel. Automated patch clamp of iPSC-CMswould combine the high accuracy with a considerable throughput but
has still its limitations in terms of purity and selection of the cell
population to be analyzed [21–23].
2.1.2. Multielectrode arrays
Multielectrode arrays (MEAs) provide a non-invasive and non-
terminal method for studying cardiomyocyte electrophysiology. Cells
are plated on a dish containing electrodes on the bottom, and ﬁeld po-
tential is recorded. Field potential duration (FPD) and the ﬁeld potential
waveform provide information at least partially comparable to action
potential data obtained from patch clamp [24,25]. MEA analysis has
been used for predicting cardiotoxicity [26] and is also rather easy to
scale up towards high throughput [27]. However, despite the efforts of
producing a “single cell MEA”, the current MEAs are able to reliably re-
cord data only from cell clusters or monolayers.
2.1.3. Fluorescent imaging
Methods based on ﬂuorescence microscopy, such as calcium indica-
tors or voltage-sensitive dyes, provide a non-invasive method for
obtaining accurate data on intracellular ion ﬂuctuations and voltage
changes. However, the addition of a chemical indicator, which attaches
to molecules inside the cell, is likely to interfere with the functioning of
the cell, which must be always kept in mind when interpreting the
results. Currently available calcium indicators, such as Fura-2 and
Fluo-4, are toxic, and UV-light, which typically is used in detection, is
also harmful for the cells [28]. Fusion genes based on green ﬂuorescent
protein (GFP) have been developed to circumvent this issue, but it
might affect the folding and functioning of the proteins in the cell, and
still needs the UV excitation. Traditional calcium imaging is a rather
slow method, both for performing the assay itself and for data analysis,
despite novel tools created for data analysis [29]. An approach towards
higher throughput in calcium imaging, capable of analyzing hundreds of
cells simultaneously on a multi-well plate, has been described a few
years ago [30]. Voltage-sensitive dyes, such as di-4-ANEPPS, respond
to changes in membrane potential by changing their ﬂuorescence
emission. They are commonly used for studying whole hearts but
have their limitations in single cell and monolayer imaging due to the
cytotoxicity [31,32].
2.2. Methods for analyzing mechanical beating behavior
Although in the majority of the studies the different methods for
assessing only the electrophysiology of the cells are used, alternative
methods would be clearly justiﬁed and even required. All genetic
cardiac diseases do not alter only the electrophysiology of the cell but
also the mechanical beating behavior, such as beating motion or
contractile force [33–36].
2.2.1. Traction force microscopy
The force exerted by a cardiomyocyte during a contraction can be
estimated with non-invasive methods using traction force microscopy.
In traction force microscopy, ﬂuorescent beads are embedded in a sub-
strate, on which cells are cultured. The displacement of the ﬂuorescent
beads due to the cell activity can then be tracked with optical methods
and cell traction force can be estimated from the displacement and the
mechanical properties of the substrate [37]. The calculationmethods for
displacement of beads are essentially similar to the ones used in video
analysis of cardiomyocytes. Hazeltine and colleagues successfully mea-
sured humanpluripotent stem cell (hPSC) derived cardiomyocyte activ-
ity in 2012 [38].
2.2.2. Atomic force microscopy
Atomic force microscopy (AFM) is another method for measuring
cardiomyocyte force. In AFM, a small cantilever is brought in contact
with the cell being measured. While the cell beats, the vertical move-
ment of the cell membrane is tracked producing the beating signal
Fig. 2. (A) Summary of themain characteristics of themethods currently used for iPSC-CM functionality analyses. Blue background color indicatesmethods assessing electrophysiology or
ion ﬂuctuations of the cell, and green color methodsmeasuring beating force ormovement of the cell. Leftmost graphic showswhether themethod utilizes electrophysiology inmeasure-
ment, or is based onmicroscopy. (B) Illustration of a cell showing different measurable properties of a cardiomyocyte alongwith themethods used to analyze those. Numbers refer to the
methods in panel A.
1866 E. Laurila et al. / Biochimica et Biophysica Acta 1863 (2016) 1864–1872[39]. hPSC derived cardiomyocyte beating characteristics have been
measured with AFM in 2012 by Liu and colleagues [40].
2.2.3. Impedance assays
Assays based on cellular impedance offer a non-invasive and label-
free analysis method, which has potential for higher throughput [28,
41]. Cells are seeded and allowed to attach on a multi-well cell culture
plate, which contains electrodes on the bottom. When a weak electric
current is applied between the electrodes, the cells attached on the
electrodes impede especially the low frequency current ﬂow as the
cell membrane has high electric impedance. When the cells are moving
or beating on top of the electrodes the impedance signal varies accord-
ingly [42]. Thus this method detects the beating indirectly from the
varying impedance signal based on mechanical movements of the
cells. Several characteristics of the cardiomyocyte beating, including
beating frequency, can be read from the output.
2.2.4. Video microscopy
In recent years, several different light microscopy methods for
analyzing the mechanical beating behavior of cardiomyocytes have
been published. The basic features and summary of the data obtained
by these methods are summarized in chapter 5 and Table 2. All thesemethods are based on a video recording of a beating cell or area,
which is then analyzed by different computational methods. Video
based analysis lacks the information of the electrophysiology of the
cell, as well as the three dimensional movement, but is a good approach
for quick and yet reliable screening of the mechanical beating behavior
of cardiomyocytes in high throughput.
2.3. Combining electrophysiology and beating mechanistics
Although measured separately, the electrophysiology, contractile
force and mechanical beating behavior of a cardiomyocyte are always
connected [43–45]. To understand this in more detail, combining and
comparing data from differentmethods have been performed in several
studies [46–48]. Calcium imaging provides a solid base for studying
electromechanical coupling in healthy cells. In the presented studies,
calcium measurements were used for validating the mechanical move-
ment measured with optical methods. Hayakawa and colleagues found
that the maximum calcium concentration in cytosol and maximum
shortening velocity occurred nearly at the same time [46]. Huebsch
and colleagues, using their cardiomyocytes with genetically encoded
calcium indicators found that calcium ﬂux and contractile motion
were spatially and temporally correlated [47]. The motion lagged by
Fig. 3. Effect of temperature on the beating frequency of iPSC-CMs. Beating frequency in
BPM (beats per minute) of one representative cell (total n = 6 per experiment) are
shown for increasing (A) and decreasing (B) temperatures, as well as constant 37 °C
temperature over a time period of 60 min (C).
1867E. Laurila et al. / Biochimica et Biophysica Acta 1863 (2016) 1864–1872several milliseconds after that rise of calcium rise and that rapid low-
intensity calcium ﬂuctuations did not cause mechanical motion. Ahola
and colleagues used patch clamp as a reference study for validating
the motion [48]. They found the time difference between the action
potential peak and maximum displacement to be approximately
300 ms and found it to correlate with previously reported values.
3. Optimizing and standardizing the analysis conditions
Regardless of the analysis tool or method used, the importance of
optimizing and standardizing of the measurement and analysis condi-
tions cannot be overestimated. These cover both the properties of the
cells to be analyzed and the external conditions before and during the
experiment process.
3.1. Cardiomyocytes
Many of themethods are capable of analyzing cells in varying densi-
ties, but the outcome may vary greatly between single cells and cell
sheets. Plating density has been shown to have effect on several differ-
ent characteristics of cardiomyocytes, including gene expression proﬁle
and electrophysiological properties [49]. In cell clusters where other cell
types than cardiomyocytes may also be present, the difference
compared to single cardiomyocytes is likely to be even larger. In addi-
tion to the cell density, the age and maturation state of the cells is an
important issue. Although there is no single correct answer to the ques-
tions “How old the cells should be?” and “What is mature enough?”,
thesemust be carefully assessed and standardized to obtain comparable
results. Finally, the external cell culture and analysis conditions, such as
culture medium, pH, gases, and temperature, must be optimized and
standardized for each experiment set-up. In the next chapter, this is
further studied and discussed from the perspective of video analysis
methods, but the basic principles are applicable for any cardiomyocyte
functionality assay.
3.2. External analysis conditions
Concerns about recording conditions, such as temperature and pH,
are true for any cardiomyocyte assay. However they are taken into
account if the more sophisticated experimental set-ups are used. For
example, in patch clamp constant perfusion with pre-warmed buffer,
typically HEPES based buffer, is used, allowing constant control of
the temperature and pH. Additionally, calcium imaging is done with
perfusion and heating systems. With more modern methods the exter-
nal perfusion and heating have not been always clearly stated or
standardized. Video based analysis of cardiomyocytes for example is
a relatively easy and quick method and recording of the video only re-
quires a good quality video camera mounted on a standard microscope.
However, the recording conditions may greatly affect the beating char-
acteristics of the cells, which then are reﬂected on the results. Although
the equipment needed for video based analysis is not extremely costly
or sophisticated, special attention should be paid on the recording
conditions to obtain reliable results.
To illustrate the effect of two variables, temperature and time, on the
cardiomyocyte beating, we performed a set of experiments and record-
ed videos while controlling these variables. UTA.04602.WT iPS cell line,
generated from a healthy individual and thoroughly characterized [36],
was used in all the experiments. Cardiac differentiation was done using
the END-2 co-culture method [36], and videos of single beating
cardiomyocytes were recorded in controlled temperature at 60 fps as
previously described [50]. Nikon (Nikon, Tokyo, Japan) Eclipse TS100
microscope and Imperx (Imperx, Boca Raton, FL, USA) IGV-B1620M
camera were used for all recordings.
The heating plate was set to 38 °C, resulting in a temperature of
approximately 37 °C in the bottom of wells of the cell culture plate.
Temperature was measured from the medium inside the well, as closeto the bottom as possible without touching the plate (temperatures
shown in Fig. 3), and the reading given by the heating platewas record-
ed at the same time. For the experiments where the temperature was
manipulated, the end point of the experiment was when the beating
of the cell was either stopped (increasing the temperature) or too
weak for reliable analysis (decreasing the temperature). For the
constant 37 °C temperature experiment, end point was set at 60 min.
Perfusion and gas exchange were not used.
First wewanted to show how increasing or decreasing the recording
temperature alters the cardiomyocyte beating characteristics (Fig. 3).
The cell tolerates surprisingly high temperatures without completely
stopping from beating (Fig. 3A). However, at high temperature the
1868 E. Laurila et al. / Biochimica et Biophysica Acta 1863 (2016) 1864–1872beating quickly gets too faint to be analyzable without a recording set-
up of greater resolution power. Lowering the temperature rather quick-
ly leads to the cells to stop beating, underlining the importance of the
use of a heating plate or perfusion (Fig. 3B). It is important to notice
that even when using a heating plate on the microscope, the tempera-
ture of the cells slightly drops as soon as the cells are removed from
the incubator. Fig. 3C illustrates how the beating frequency of the cells
dramatically drops almost 50% in the course of time, even when the
recordings are performed on a heating plate at standard temperature.
This could be due to changes in other parameters in the cell culture,
e.g. change in pH or O2/CO2, since these were not standardized in this
experiment.
In the set-up for patch clamp or other electrophysiological analysis
of cardiomyocytes these issues are usually well addressed. In the vast
majority of the studies summarized in Table 1 in Section 4, the electro-
physiological analyses were performed in temperatures between 32
and 37 °C. Our experiments underline the importance of carefully
controlling the recording conditions, even though the basic set-up for
recording videos of beating cardiomyocytes is rather simple. Simply
the use of a standard stage incubator would solve most of the issues
described above. However, experiments to verify the quality of record-
ing conditions and set-up are certainly recommended.
4. Overview of the commonly used methods
To review the methods commonly used for the characterization
of the iPSC disease models of genetic cardiac diseases, we analyzed
25 studies utilizing iPSC technology in modeling genetic cardiac disor-
ders and summarized the characterization methods used in those
(Table 1). Studies were selected from those published during the past
ﬁve years. Papers in which no characterization methods were used,
such as gene expression related approaches, were excluded. AsTable 1
Summary of the methods used for the functional characterization of iPSC models for ge-
netic cardiac diseases in 25 studies from the past ﬁve years.
Reference Disease pClamp Ca2+ MEA Others
Bellin et al. [53] LQT2 x x
Caspi et al. [54] ARVC x
Di Pasquale et al.[55] CPVT x x
Egashira et al. [56] LQT1 x x
Fatima et al. [57] CPVT x x x
Fatima et al. [58] LQT3 x
Han et al. [59] HCM x x x
Itzhaki et al. [60] LQT2 x x
Itzhaki et al. [61] CPVT x x x
Jung et al. [62] CPVT x x
Kiviaho et al. [36] LQT1 x x Video analysis
Kujala et al. [63] CPVT x x
Lahti et al. [34] LQT2 x x
Lan et al. [51] HCM x x Video analysis
Lin et al. [64] DCM x x
Ma et al. [65] LQT3 x
Ma et al. [66] ARVC x x
Ma et al. [67] LQT1 x
Matsa et al. [68] LQT2 x x
Mehta et al. [69] LQT2 x x
Novak et al. [70] CPVT x x
Spencer et al. [71] LQT2/3 x x
Sun et al. [52] DCM x x Atomic force microscopy
Terrenoire et al. [72] LQT2 x
Yazava et al. [73] LQT8 x x
ARVC arrhythmogenic right ventricular cardiomyopathy
BTHS Barth syndrome
Ca2+ calcium imaging or similar ﬂuorescent imaging method
CPVT catecholaminergic polymorphic ventricular tachycardia
DCM dilated cardiomyopathy
HCM hypertrophic cardiomyopathy
LQT long-QT
MEA multielectrode array
pClamp patch clampexpected, the main method for studying cardiomyocyte functionality
is patch clamp, whichwas used in all but one study. Typically the exper-
imental approach was to use patch clamp accompanied by one addi-
tional method, usually either calcium imaging or multielectrode array.
The additional methods are usually chosen bymolecular defect present
in the disease — for example in CPVT (catecholaminergic polymorphic
ventricular tachycardia) the disease is due to disturbances in calcium
transients in the cells, and thus calcium imaging is the most suitable
method to describe the phenotype. In two studies, the cardiomyocytes
were also analyzed based on video recordings of the cells [36,51] and
one study utilized atomic force microscopy to analyze the cells [52]. In
summary, the studies favor strongly the traditional methods, but are
occasionally including also additional methods, if suitable in the re-
search approach.
5. Details of the methods based on video microscopy
Video microscopy provides a non-invasive and rather easy method
for cardiomyocyte beating analysis. Furthermore, it has potential for
automatization and scaling up to achieve higher throughput. In recent
years, a variety of methods for video microscopy based cardiomyocyte
analysis has been published. Basic features of these methods are sum-
marized in Table 2.
For any video microscopy method, the ﬁrst and most important
issue is the quality of the recording, which must be high enough to
achieve a sufﬁcient temporal and spatial resolution. To enable the detec-
tion of faint beating movement, the magniﬁcation and frame size must
be good enough. Naturally, the deﬁnition of “good enough” is deter-
mined by the target, whether it is a single cell, a small cluster of cells
or even a cell sheet or aggregate. The frame rates of the different
methods seem to have more variation. High frame rate enables the
detection of minor changes in the temporal scale. The average time
from the start of contraction to the end of relaxation is 500–600 ms if
beating rate is in the range of 40–60/min. The number of frames
captured within this time period varies approximately from four
(7 fps, frames per second) to 70 (125 fps), corresponding to a frame cap-
tured every 143 or 8 ms, respectively. For example when screening the
safety of novel drug candidates, a 30–50 millisecond prolongation in
contraction–relaxation phase could be classiﬁed as signiﬁcant, the dif-
ferencemight become signiﬁcant in detection of certain beating charac-
teristics. However, somemethods described later on in this review only
aim to detect changes in the beating frequency, for which lower frame
rates are sufﬁcient [33,74]. To be able to obtain more detailed data on
the beating phases, a higher frame rate is essential [48,50].
A commonly used procedure for generating beating signals from the
cells is to have each video frame divided into analysis regions. A degree
of similarity, or difference, between these regions in subsequent, or
later, video frames is calculated. This block matching process allows
the calculation of velocity and direction of the motion in each analysis
window, generating a velocity vector. Based on these vectors, beating
signals are calculated by calculating a measure of magnitude for each
frame. Similar displacement signals can be obtained without block
matching, as demonstrated by Liu and colleagues [33] and Maddah
and colleagues [74]. Liu and colleagues had used principal component
analysis on motion vector ﬁelds in their previous study, but in their
later study, they used it on moving textures instead. Maddah and col-
leagues calculated the correlation of each framewith a resting-state ref-
erence frame, producing a beating signal.
Kamgoué and colleagues quantiﬁed cardiomyocyte contraction
using a block-matching algorithm [75]. They used the displacement
ﬁelds to calculate displacement signals. The signals were used to study
single adult rat cardiomyocyte deformations and calculate shortening
during contraction.
Hayakawa and colleagues described an analysis method, using a
block-matching algorithm [46]. They analyzed monolayers of neonatal
rat cardiomyocytes with a high 125 fps frame rate. They observed the
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cells. To verify their ﬁndings, they performed simultaneous calcium
imaging measurements. The ﬂuorescence oscillations were consistent
with the motion vector oscillations. They also performed extensive
drug experiments. In their later studies [77], they used their
method with hiPSC-CMs. Additionally, they used multielectrode arrays
for ﬁeld potential measurements and traction force microscopy
for force measurements and improved their beating parameter calcula-
tion. Their methodwas further used for cardiomyocyte directional anal-
ysis in a clinical study on HCM (hypertrophic cardiomyopathy) cells
[78].
Liu and colleagues presented an analysismethod,which usesmotion
based deformation registration instead of block matching [33]. It uses
principal component analysis on moving textures to reduce computa-
tional load. This is based on the observation that for small motion, the
moving texture and motion ﬁelds are linearly related [81]. The frame
rates used were 15 and 30 fps. Themethod allows automatic segmenta-
tion of regions based on their beating rhythm.
Ahola and colleagues introduced an analysis method for hiPSC
derived cardiomyocytes [48]. Blockmatching usingminimumquadratic
difference was used for generating the vector ﬁelds for single cells. They
deﬁned beating focus points to determine beatingmotion direction and
divided the cell further into sectors. They used 30 fps recordings. Their
method was later improved by calculating correlation-based averaged
waveforms, which showed the importance of using higher frame rates
and the advantage of measuring signals from multiple parts of the
same cell [50]. The method was used in a clinical study on LQT (long
QT) cells, in which the method was improved to study the beating
phases in more detail [36].
Maddah and colleagues presented an analysis pipeline, which
enables automated analysis of large areas [74]. It addresses the
concerns related to differences in culture density by segmenting the im-
ages into regions that beat, non-beating regions and background. In-
stead of commonly used block matching, their approach creates
signals from calculating correlation coefﬁcients from these regions.
They used hiPSC derived cardiomyocytes in their study and recorded
the videos with 24 fps.
Chen and colleagues analyzed hESC derived cardiomyocyte
monolayers with their block matching algorithm [76]. They studied
cardiomyocyte orientation and beating on a wrinkled substrate. With
the method, they calculated motion directions on cell culture levels
and determined contraction and relaxation phases. The frame rates
were 7 and 20 fps. The method was later used in a platform, which
automates the detection of drug effects using machine learning [79].
Huebsch and colleagues presented a method, which uses block
matching [47]. They combined their analysis withGCaMP6f, a genetical-
ly encoded calcium indicator and studied single cardiomyocytes and
clusters. Theirmethod addresses some concerns of user bias by automa-
tion. They used frame rates 14 fps and 100 fps. Similarly as Ahola and
colleagues [48], their method also uses beating center points for
calculating velocities in different directions.
The methods described above represent the array of video based
cardiomyocyte studies. The availability of human pluripotent stem
cells has changed the focus of method development from mouse and
rat cells to human cells. hESC and hiPSC derived cardiomyocytes do
not resemblemature adult cardiomyocytes due to their less mature sar-
comere structure. The difference in sarcomeric structure results in fusi-
form beating patterns, similar to those in neonatal rat cardiomyocytes
and different from human adult cardiomyocytes. This difference has
an effect on video analysis, as the directionality of the beating needs to
be considered. This issue was approached by Ahola and colleagues by
producing multiple beating signals from different parts of the cell [48].
However, the way these cellular subregions are deﬁned warrants
further research.
The majority of methods include a block matching algorithm, with
the noted exceptions, and a measure of displacement used to produce
1870 E. Laurila et al. / Biochimica et Biophysica Acta 1863 (2016) 1864–1872the signal. A commonly used measure is calculating the average
beating velocity for a region of interest. However, there are somemeth-
odological problems related to this measurement. For cardiomyocyte
monolayers, determining the ROI (region of interest) for calculating
average displacement from cultures with multiple beating areas is not
explicit. In calculating the average beating velocity, the other beating
areas may have an effect on the result. Maddah and colleagues
addressed this problem with their automatic analysis method [74]. For
single cardiomyocytes, adhesion can have an effect on the measure-
ments. Computing the average beating velocity may produce different
results when including the non-moving areas near the cell boundaries
and when only a small region from the center of the cell is considered.
Further, these measurements by themselves do not provide directional
information and the obtained beating signals show contraction and
relaxation occurring in the same direction. For a directional signal, a
frame of reference would need to be set, as was done by Ahola and
colleagues and by Huebsch and colleagues [47,48].
Frame rates vary in the presented studies from 7 fps in orientation
studies by Maddah and colleagues [74] to 150 fps by Tanaka and
colleagues [78] for clinical studies. However, cardiomyocytes with
LQT1 mutation were characterized with only 30 fps by Kiviaho and
colleagues [36]. Ahola et al. considered this issue in briefwhen assessing
the effect of frame rate on creating averaged waveform templates [50].
Due to the small sample size, the study would need to be repeated to
provide more detail. Conclusive guidelines for frame rate selection
have yet to be determined andwill even then depend on the application
and the phenotype of the cell motion.
6. Conclusions
The methodology for functional in vitro analysis of cardiomyocytes
is developing rapidly. Traditional electrophysiological methods have
been accompanied by novel approaches, aiming at faster and easier,
yet reliable analysis of cardiomyocyte beating characteristics. In
addition to the videomicroscopymethods, discussed in detail in this re-
view, the entire ﬁeld of optical imaging methods has advanced in the
last few years. Optogenetic technologies are likely to evolve rapidly
[31], novel innovations for single cell analysis can be expected in the
near future [20], and the recent advances in in silico modeling offer
great support for the in vitro analyses [82].
7. Future perspectives
In the human body, the cardiomyocytes are always surrounded by
cells, both cardiomyocytes and other cell types. Cardiomyocyte func-
tionality can be assessed on different levels, starting from the analysis
of single cells all the way to studying the entire organ. Cell culture
based methods are typically concentrating on the smaller end of the
size scale (mainly single cells to small aggregates). Studying single
cells is likely to reveal more detailed information of the molecular
mechanisms of the disease since in a heterogeneous cluster of cells
the disease phenotype might be covered by the other types of cells or
mixture of different types of cardiomyocytes [53,83]. Publications
from the last decade have shown great progress on simulating a
much more physiological environment by creating engineered heart
tissues (EHT) [84]. EHT is a structure, which consists of not only
cardiomyocytes but also cardiac ﬁbroblasts and/or endothelial cells,
and provides a more complex model for studying cardiomyocyte
biology. This approach has been used especially in studying myocardial
injuries but has been aimed for drug safety screening as well [9,80,84].
Obviously, the ﬁndings from cell based assays cannot be directly com-
pared to the organ level, even when performed in a tissue mimicking
environment. However, some results from the cellular level have been
shown to nicely correlate to the actual physiological events in the
patients, such as the mutation-speciﬁc, antiarrhythmic effects of
dantrolene in CPVT patients [85], demonstrating the future potentialof iPSC based disease modeling and optimizing treatments in patient-
speciﬁc manner in the future.
Individualized therapy is certainly the future goal thatwe are aiming
to reach. However, it is obvious that the routine testing ofmedication on
patient-speciﬁc cells will require even more high throughput than the
currently available tools can provide. For larger scale individualized
therapy, also methods to obtain patient-speciﬁc cardiomyocytes
have to be improved, e.g. direct transdifferentiation of blood or skin
to cardiomyocytes, iCMs [86]. In the future, the basic clinical care of a
patient with a genetic cardiac disease might include screening of
compound libraries with patient-speciﬁc iPSC-CMs or induced
cardiomyocytes, iCMs, to optimize the medication. The perfect future
method would combine sensitivity, reliability, low cost and high
throughput into one single assay. Thus, the further investigation and
development of the methods described in this article, as well as novel
innovative approaches are crucial for this goal to be reached.
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